Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Nephrotoxic potential of selective cyclooxygenase-2 inhibitors.

Sandhu GK, Heyneman CA.

Ann Pharmacother. 2004 Apr;38(4):700-4. Epub 2004 Feb 24. Review.

PMID:
14982980
2.

Use of NSAIDs for the chemoprevention of colorectal cancer.

Herendeen JM, Lindley C.

Ann Pharmacother. 2003 Nov;37(11):1664-74. Review.

PMID:
14565811
3.

COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery.

Cicconetti A, Bartoli A, Ripari F, Ripari A.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Feb;97(2):139-46.

PMID:
14970772
4.

Adverse Drug Events Involving COX-2 Inhibitors.

Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL.

Ann Pharmacother. 2003 Sep;37(9):1203-13.

PMID:
12921500
5.

Renal effects of cyclooxygyenase-2-selective inhibitors.

Brater DC.

J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S15-20; discussion S21-3. Review.

PMID:
11992745
6.

Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.

Grover JK, Yadav S, Vats V, Joshi YK.

Int J Colorectal Dis. 2003 Jul;18(4):279-91. Epub 2002 Nov 19. Review.

PMID:
12774242
7.
8.

Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.

Komers R, Anderson S, Epstein M.

Am J Kidney Dis. 2001 Dec;38(6):1145-57. Review.

PMID:
11728945
9.
10.

Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.

Jacobsen RB, Phillips BB.

Ann Pharmacother. 2004 Sep;38(9):1469-81. Epub 2004 Jun 22. Review.

PMID:
15213313
11.

Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.

Morales E, Mucksavage JJ.

Pharmacotherapy. 2002 Oct;22(10):1317-21. Review.

PMID:
12389882
12.

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

Mukherjee D.

Biochem Pharmacol. 2002 Mar 1;63(5):817-21. Review.

PMID:
11911832
13.

What are the risks of long-term NSAIDs and COX-2 inhibitors?

DeBisschop M.

J Fam Pract. 2003 Mar;52(3):199-200.

PMID:
12620173
14.

Clinical pharmacology of novel selective COX-2 inhibitors.

Tacconelli S, Capone ML, Patrignani P.

Curr Pharm Des. 2004;10(6):589-601. Review.

PMID:
14965322
15.

Cyclooxygenase-2 inhibitors: promise or peril?

Mengle-Gaw LJ, Schwartz BD.

Mediators Inflamm. 2002 Oct;11(5):275-86. Review.

16.

Osteoarthritis therapy--are there still unmet needs?

Laufer S.

Rheumatology (Oxford). 2004 Feb;43 Suppl 1:i9-15. Review.

PMID:
14752170
17.

The therapeutic potential of NO-NSAIDs.

Wallace JL, Del Soldato P.

Fundam Clin Pharmacol. 2003 Feb;17(1):11-20. Review.

PMID:
12588626
18.

Acute renal dysfunction associated with selective COX-2 inhibitor therapy.

Papaioannides D, Bouropoulos C, Sinapides D, Korantzopoulos P, Akritidis N.

Int Urol Nephrol. 2001;33(4):609-11.

PMID:
12452607
19.

The COX-2 inhibitors: new analgesic and anti-inflammatory drugs.

Khan AA, Dionne RA.

Dent Clin North Am. 2002 Oct;46(4):679-90. Review.

PMID:
12436824

Supplemental Content

Support Center